Tolimidone NEW
| Price | $43 | $70 | $119 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Tolimidone | CAS No.: 41964-07-2 |
| Purity: 99.85% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Tolimidone |
| Description | Tolimidone (NSC 314335) is a chemical compound which inhibits acid secretion in animal models and also acts as a bronchodilator in histamine-challenged animals. |
| Cell Research | Adipocyte differentiation is assessed in mouse 3T3-L1 cells after 8 days of incubation with MLR-1023 or rosiglitazone (10 μM).(Only for Reference) |
| In vitro | In an in vitro broad kinase screen MLR-1023 activated the nonreceptor-linked Src-related tyrosine kinase Lyn. MLR-1023 increased the Vmax of Lyn with an EC50 of 63 nM. This Lyn kinase activation was ATP binding site independent, indicating that MLR-1023 regulated the kinase through an allosteric mechanism[1]. |
| In vivo | MLR-1023-mediated blood glucose lowering depends on Lyn kinase activity[1]. MLR-1023 is an insulin receptor-potentiating agent that produces a rapid-onset and durable blood glucose-lowering activity in diabetic animals[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (9.89 mM), Sonication is recommended. DMSO : 125 mg/mL (618.17 mM), Sonication is recommended. 10% DMSO+90% Saline : 10 mg/mL (49.45 mM), Solution. Ethanol : 4 mg/mL (19.78 mM), Sonication is recommended. |
| Keywords | Tolimidone | Src | NSC-314335 | NSC314335 | MLR1023 | MLR 1023 | Lyn kinase | Inhibitor | inhibit | CP26154 | CP 26154 |
| Inhibitors Related | Nintedanib | Vemurafenib | SI-2 hydrochloride | Staurosporine | Dasatinib | Ibrutinib | iHCK-37 | Pelitinib | Tofacitinib | Dasatinib monohydrate | TAK-901 | MCB-613 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Diabetic Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Metabolism Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2025-12-24 | ||
| $1.00 |
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-02-26 | |
| $1.00 |
VIP7Y
|
Career Henan Chemical Co
|
2020-01-13 | |
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-02-26 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY